Proteome Sciences PLC AGM Statement (5142L)
2022年5月16日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMPRM
RNS Number : 5142L
Proteome Sciences PLC
16 May 2022
16 May 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Annual General Meeting (AGM) Statement
At the Company's AGM being held today at 12.00 noon, the
Chairman, Christopher Pearce, will make the following
statement:
"With continuous business growth and a particularly good
performance in our service business, we recorded a small profit and
an adjusted EBITDA* of GBP1.35m (2020: GBP0.72m) for the year ended
31 December 2021. We were able to gain a record number of contracts
including a substantial order in excess of GBP1m. Also, our TMT
revenues remained strong underlining the USP we have in the
proteomics field with these reagents. Based on the strategic
process we ran in 2021 we decided to add a high value, high demand
service to our portfolio -single cell proteomics - and to increase
our USP of proprietary tags by developing new, innovative reagents.
The progress over the last three years has created an excellent
platform for the further development of the company. The strong
order book, cash position and strategic plan provide a basis to
grow all aspects of our business in 2022. We started strategic
investments in staff and instruments in 2021 and continue to do so
in 2022. The board has an increased confidence of profits growth in
2022."
* - Adjusted EBITDA is a non-GAAP company specific measure which
is considered to be a key performance indicator of the Group's
financial performance. Adjusted EBITDA is calculated as operating
profit before depreciation (including right-to-use assets
amortisation), amortisation, non-recurring costs, and employee
share-based payment.
For further information:
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive
Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMAJMFTMTBBBJT
(END) Dow Jones Newswires
May 16, 2022 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
過去 株価チャート
から 11 2024 まで 12 2024
Proteome Sciences (AQSE:PRM.GB)
過去 株価チャート
から 12 2023 まで 12 2024